Medicine,
‍Redefined.

We are pioneering Hybrid Drugs™ – a new therapeutic category designed to integrate traditional medication with innovative digital interventions.

Hybrid Drugs aim to enhance motor, cognitive, and mental function, and measurably improve outcomes via AI driven digital daily protocols.

Enter Hybrid DrugsTM

Two Mechanisms. One Unified Treatment.

Remepy’s Hybrid Drugs are not "apps paired with pills." They integrate two complementary mechanisms of action, designed to increase clinical benefit:

01 The Molecule

The Pharmacological Pathway

Pharmaceuticals that target core biological drivers of disease, or treat disease symptoms. What is generally referred to as traditional medication today.

02 The Protocol

The Behavioral-Digital Pathway

An adaptive digital layer targets the neural and behavioral circuits that drugs cannot reach. Through specific, research-based motor, cognitive, and autonomic interventions, this layer rewrites neural patterns and reinforces therapeutic routines. The digital intervention and pharmacological treatment are designed to work together to achieve the intended therapeutic effects of the combination product.

The Result

A synergistic effect where the drug enables function, and the digital protocol reinforces and enhances it, with the goal of achieving better clinical outcomes that neither could achieve alone.

Why Medicine Alone Is No Longer Enough

For decades, traditional drugs have relied on primarily on chemistry.
While pharmaceuticals excel at targeting biological pathways, they don't address the full complexity of human health.

Chronic conditions are driven by many factors beyond biology. They’re influenced by behavior, cognitive state, and patient lifestyle. Traditional drugs are static; they don't adapt to the patient’s changing needs once they leave the pharmacy. To improve outcomes, we need medicines that address both the biology of the disease and the reality of the patient.

Medicines That Learn & Adapt

Unlike a static pill, a Hybrid Drug evolves. Our proprietary platform uses real-time data to personalize the intervention to the patient's specific profile. These interventions combined with the traditional medication aim to drive enhanced biological mechanisms and improve patient outcomes.

  • Personalized Dosing & Support

    The digital layer adjusts based on the patient's daily fluctuations.

  • Neuroplastic Engagement

    Protocols are designed to engage specific brain networks—such as the motor cortex in Parkinson’s or stress-regulation pathways in Oncology.

  • Continuous
    Care

    The treatment doesn't stop when the pill is swallowed; it provides continuous therapeutic engagement at home.

  • Single Source of Care

    Consolidating all relevant therapies into one unified platform helps simplify the daily routine, making it easier for patients to follow - with the goal of improving long-term adherence.

Regulated Like a Drug. Reimbursed Like a Drug.

Hybrid Drugs represent a fundamental shift in how digital health is delivered. We do not sell "wellness apps." We develop regulated therapeutics.

  • FDA Pathways

    We pursue FDA regulatory pathways for drug-software combination products, including the Drug-SaMD framework and PDURS (Prescription Drug Use-Related Software) guidance.

  • Clinical Validation

    We hold our products to the same rigorous standards as traditional pharma, advancing through Phase 2 and Phase 3 clinical trials to evaluate efficacy and safety.

  • Seamless Access

    Hybrid Drugs are intended to be prescribed by doctors and reimbursed by payers, fitting seamlessly into the existing healthcare infrastructure.

Applying the Hybrid Model

We are currently applying our Hybrid Drug platform to some of the most complex challenges in medicine. We target drugs for diseases where meaningful changes to brain connectivity, changes to the immune system, and behavioral changes are synergistic with drug effects. Current focus areas include:

Oncology

Description: Addressing the high burden of toxicity & distress in cancer treatment. Our hybrid approach aims to improve tolerability and extend survival outcomes through autonomic regulation.

Status: Strategic Partnership / In Development.

Parkinson’s Disease

Description: Our lead program, Hybridopa™, combines immediate release levodopa-carbidopa with a digital protocol designed to target signs and symptoms of Parkinson’s disease.

Status: Phase 2 Completed. Phase 3 coming soon.

Women's Health

Description: Targeting underserved conditions where hormonal biology and behavioral health intersect, offering a new standard of care for complex, life-stage specific conditions.

Status: In Development.

Partner with the Pioneer.

Remepy is defining the next era of pharmaceutical development. We partner with top-tier pharma companies to extend the lifecycle of their assets and improve patient outcomes.